Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 3 4Phase NA 3Phase 1 3Phase 4 2Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 699Breast Neoplasms 629Neoplasms 582Leukemia, Myeloid, Acute 481Colorectal Neoplasms 455Multiple Myeloma 444Melanoma 424Prostatic Neoplasms 383Neoplasm Metastasis 370Pancreatic Neoplasms 361Recurrence 347Lymphoma 340Ovarian Neoplasms 322Lung Neoplasms 297Lymphoma, Non-Hodgkin 295Leukemia 287Glioblastoma 275Precursor Cell Lymphoblastic Leukemia-Lymphoma 249Stomach Neoplasms 246Leukemia, Lymphocytic, Chronic, B-Cell 235Carcinoma, Hepatocellular 231Squamous Cell Carcinoma of Head and Neck 219Lymphoma, Large B-Cell, Diffuse 217Myelodysplastic Syndromes 212Carcinoma, Renal Cell 210Lymphoma, Follicular 183Head and Neck Neoplasms 172Brain Neoplasms 169Triple Negative Breast Neoplasms 167Lymphoma, Mantle-Cell 167

Interventions

MLN 8237 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Non-small Cell Lung Cancer Metastatic × Clear all
NCT01471964 2018-05-17

Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer

Fox Chase Cancer Center

Phase 1/2 Terminated
22 enrolled
Thoracic

Non-small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡